Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-04-09
2000-07-25
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514415, 548491, A61K 3140, A61K 31405, C07D20904, C07D40314
Patent
active
060937408
ABSTRACT:
A method for reducing or inhibiting vascular permeability especially the increased vascular permeability associated with VPF/VEGF, and dermal edema exhibited with bullous phemigoid, erythema multiforme, dermatitis herpetiformis, contact dermatitis/delayed hypersensitivity is disclosed, particularly using the .beta.-isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.
REFERENCES:
patent: 5057614 (1991-10-01), Davis et al.
patent: 5481003 (1996-01-01), Gillig et al.
patent: 5491242 (1996-02-01), Gillig et al.
patent: 5545636 (1996-08-01), Heath, Jr. et al.
patent: 5552396 (1996-09-01), Heath, Jr. et al.
patent: 5621098 (1997-04-01), Heath, Jr. et al.
patent: 5710145 (1998-01-01), Engel et al.
Claffey, et al., Cancer Research, 56:172-181 (1996).
Denekamp J., The British Journal Of Radiology, 66(783):181-196 (1993).
Flier, et al., The New England Journal Of Medicine, 333(26): 1757-1763 (1995).
Folkman, J., "Tumor Angiogenesis", The Molecular Basis of Cancer, Mendelsohn, et al., Pub., W.B. Saunders Company, 206-232 (1995).
Muthukrishnan, et al., Journal Of Cell Physiology, 148:1-16 (1991).
Pepper, et al., Biochemical And Biophysical Research Communications, 189(2):824-831 (1992).
Aiello, et al., The New England Journal Of Medicine, 331(22):1480-1487 (1994).
Amin, et al., Investigative Ophthalmology & Visual Science, 35(8):3178-3188 (1994).
Bird, Survey Of Ophthalmology, 28 (Supplement):433-436 (1984).
Chan, et al., Ophthalmology, 101(2):289-300 (1994).
Cunha-Vaz, et al., Survey Of Ophthalmology, 28 (Supplement):485-492.
Freund, et al., American Journal Of Ophthalmology, 115:786-791 (1993).
Friedman, et al., American Journal Of Kidney Diseases, 26(1):202-208 (1995).
Jampol, et al., Survey Of Ophthalmology, 28 (Supplement):535-539 (1984).
Kirkpatrick, et al., Br. J. Ophthalmol., 77:766-770 (1993).
Klein, et al., "Prevalence Of Age Related Maculopathy: The Beaver Dam Eye Study," Ophthalmology, 99(6):933-943 (1992).
Klein, et al., Medical Clinics Of North American, 72(6):1415-1437 (1988).
Liebowitz, et al., "The Framingham Eye Study: VI. Macular Degeneration," Survey Of Ophthalmol., 24 (Supplement):428-457 (1980).
MPS Group, Arch. Ophthalmol., 109:1232-1241 (1991).
Raskin, et al., Annals Of Internal Medicine, 117(3):226-233 (1992).
Yannuzzi, Survey Of Ophthalmology, 28:540-553 (1984).
Yannuzzi, et al., Ophthalmology, 88(9):947-554 (1981).
Van Effenterre, et al., J. Fr. Ophthalmol., 16(11):602-610 (1993).
Jacobson et al., "Anti-inflammatory Properties of Go 6850: A Selective Inhibitor of Protein Kinase C," J. of Pharm. Expl. Ther., vol. 275, No. 2, pp. 995-1002, Nov. 1995.
Jirousek Michael Robert
Stramm Lawrence E.
Vignati Louis
Ways Douglas Kirk
Darkes Paul R.
Eli Lilly and Company
Oswecki Jane
Richter Johann
LandOfFree
Therapeutic treatment for skin disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic treatment for skin disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatment for skin disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1336969